Endocrine responses during CPAP withdrawal in obstructive sleep apnoea: data from two randomised controlled trials.


Journal

Thorax
ISSN: 1468-3296
Titre abrégé: Thorax
Pays: England
ID NLM: 0417353

Informations de publication

Date de publication:
11 2019
Historique:
received: 25 04 2019
revised: 09 08 2019
accepted: 13 08 2019
pubmed: 31 8 2019
medline: 19 5 2020
entrez: 31 8 2019
Statut: ppublish

Résumé

The aim of this investigation was to elucidate the effect of CPAP withdrawal on neurometabolic and cardiometabolic markers in patients with obstructive sleep apnoea. We evaluated 70 patients (mean age 61±10 years, 82% men) treated with CPAP in two 2-week, parallel, randomised controlled trials. CPAP withdrawal resulted in elevated 3,4-dihydroxyphenylglycol, norepinephrine and cortisol after 2 weeks of CPAP withdrawal; however, no statistically significant changes of the renin-angiotensin-aldosterone system (RAAS) determinants were documented. In summary, CPAP withdrawal may be more prominently linked to short-term increases in sympathetic activation than hypothalamic-pituitary-adrenal axis or RAAS activation. ClinicalTrials.gov Identifier: NCT02493673 and NCT02050425.

Identifiants

pubmed: 31467191
pii: thoraxjnl-2019-213522
doi: 10.1136/thoraxjnl-2019-213522
doi:

Substances chimiques

Biomarkers 0
Methoxyhydroxyphenylglycol 534-82-7
3,4-dihydroxyphenylglycol UEH9K539KJ
Hydrocortisone WI4X0X7BPJ
Norepinephrine X4W3ENH1CV

Banques de données

ClinicalTrials.gov
['NCT02493673', 'NCT02050425']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1102-1105

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: MK reports grants from University of Zurich, grants from Lunge Zurich, during the conduct of the study; grants from Bayer AG (consultancy), outside the submitted work. TG reports grants from Bayer AG (consultancy), outside the submitted work.

Auteurs

Sira Thiel (S)

Department of Pulmonology and Sleep Disorders Centre, University Hospital Zurich, Zurich, Switzerland.

Sarah R Haile (SR)

Department of Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Zurich, Switzerland.

Mirko Peitzsch (M)

Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.

Esther I Schwarz (EI)

Department of Pulmonology and Sleep Disorders Centre, University Hospital Zurich, Zurich, Switzerland.

Noriane A Sievi (NA)

Department of Pulmonology and Sleep Disorders Centre, University Hospital Zurich, Zurich, Switzerland.

Salome Kurth (S)

Department of Pulmonology and Sleep Disorders Centre, University Hospital Zurich, Zurich, Switzerland.

Felix Beuschlein (F)

Department of Endocrinology, Diabetology and Nutrition, University Hospital Zurich, Zurich, Switzerland.
Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany.

Malcolm Kohler (M)

Department of Pulmonology and Sleep Disorders Centre, University Hospital Zurich, Zurich, Switzerland.
Centre for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.

Thomas Gaisl (T)

Department of Pulmonology and Sleep Disorders Centre, University Hospital Zurich, Zurich, Switzerland thomas.gaisl@usz.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH